18FDG PET for grading malignancy in thymic epithelial tumors: Significant differences in 18FDG uptake and expression of glucose transporter-1 and hexokinase II between low and high-risk tumors: Preliminary study

European Journal of Radiology

Volumn 81, Issue 1, 2012, Pages 146-151

  Nakajo, Masatoyo ^a,c   Kajiya, Yoriko ^a   Tani, Atsushi ^a   Yoneda, Satoshi ^b   Shirahama, Hiroshi ^b   Higashi, Michiyo ^c   Nakajo, Masayuki ^c  

^a Nanpuh Hospital   (Japan)

^b Imakiire General Hospital   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

FDG PET; Glucose transporter 1; Hexokinase II; SUV max; Thymic epithelial tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE ISOENZYME; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; HK1 PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EPITHELIUM TUMOR; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYMOMA; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK FACTORS; THYMUS NEOPLASMS;

EID: 84855536506     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2010.08.010     Document Type: Article

References (25)

1. Rosai J, Sovin LH. Histological typing of tumors of the thymus. International histological classification of tumors. 2nd ed. New York, Berlin: Springer; 1999. pp. 5-15.
2. Okumura M, Miyoshi S, Fujii Y, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am J Surg Pathol 2001;25(1):103-10. (Pubitemid 32001839)
3. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95(2):420-9. (Pubitemid 34787609)
4. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002;94(3):624-32. (Pubitemid 34132289)
5. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23(12):1641-74.
6. 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 2008;33(5):1047-54.
7. Liu RS, Yeh SH, Huang MH, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med 1995;22(12):1402-7.
8. Kubota K, Yamada S, Kondo T, et al. PET imaging of primary mediastinal tumors. Br J Cancer 1996;73(7):882-6. (Pubitemid 26110157)
9. Sasaki M, Kuwabara Y, Ichiya Y, et al. Differential diagnosis of thymic tumors using a combination of 11C-Methionine PET and FDG PET. J Nucl Med 1999;40(10):1595-601. (Pubitemid 29471147)
10. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med 2006;47(10):1628-34.
11. 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 2008;61(3):350-5.
12. 18F-FDG PET-CT. Ann Nucl Med 2009;23(6):569-77.
13. El-Bawab H, Al-Sugair AA, Rafay M, Hajjar W, Mahdy M, Al-Kattan K. Role of fluorine-18 fluorodeoxyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg 2007;31(4):731-6. (Pubitemid 46400514)
14. Tomiyama N, Johkoh T, Mihara N, et al. Using the World Health Organization classification of thymic epithelial neoplasms to describe CT findings. Am J Roentgenol 2002;179(4):881-6.
15. 18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci 2008;99(2):260-6.
16. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stage. Cancer 1981;48(11):2485-92. (Pubitemid 12228012)
17. Shimosato Y, Mukai K, Matsuno Y. Tumors of the mediastinum. In: Silverberg SG, editor. AFIP atlas of tumor pathology. 4th Series Fascicle 11. Silver Spring, Maryland: ARP Press; 2010. p. 19-55.
18. 18F] FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7(4):369-79.
19. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56(5):1164-7. (Pubitemid 26065417)
20. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y, Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998;11(5):437-43. (Pubitemid 28224445)
21. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997;29(4):339-43.
22. 18F-fluorodeoxyglucose positron emission tomography and expression of Glut-1 and -3 and hexokinase I and II in high-grade glioma. Oncol Rep 2008;20(3):537-42.
23. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002;43(2):173-80.
24. De Geus-Oei LF, van Krieken JH, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55(1):79-87. (Pubitemid 46038871)
25. Godoy A, Ulloa V, Rodríguez F, et al. Differential subcellular distribution of glucose transporters GlUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006;207(3):614-27.